Oragenics INC 8-K filings

Oragenics, Inc. announced the appointment of John Spencer as Chief Financial Officer and shareholder approval for a reverse stock split, alongside director re-elections and auditor ratification.

Oragenics provides an update on its Phase IIa ONP-002 trial in Australia, patient enrollment progress, and a Letter of Intent for a complementary CNS medical device.

Oragenics, Inc. has signed a Letter of Intent to license Sigyn Therapeutics' CardioDialysis technology, aiming to target Traumatic Brain Injury (TBI) induced systemic inflammation.

Oragenics has dosed the first patient in its Phase IIa clinical trial for ONP-002, a potential treatment for concussion and mild traumatic brain injury, in Australia.

Oragenics, Inc. announced a change in the date for its 2025 Annual Meeting of Shareholders to June 29, 2026, setting a new deadline for shareholder proposals.

Oragenics, Inc. amended its At-the-Market Sales Agreement with Dawson James Securities Inc. to extend the term for future common stock sales.

Oragenics, Inc. announced its CEO will present at the Sequire Investor Summit on January 20, 2026, utilizing a new investor presentation.

Oragenics, Inc. announced a 5% salary increase for CEO Janet Huffman and significant stock option awards for both the CEO and non-employee directors.

Oragenics, a clinical-stage biotech, reported key Q3 2025 operational, financial, and strategic achievements, including regaining NYSE American compliance and advancing its lead therapeutic candidate, ONP-002.

Oragenics, Inc. announced it has regained full compliance with NYSE American listing standards and secured significant capital to advance its lead clinical program.

Oragenics, Inc. announced the appointment of seasoned pharmaceutical and healthcare executive Natasha Giordano to its Board of Directors, effective September 1, 2025.

Oragenics, Inc. announced significant progress in its brain-first recovery platform, including clinical milestones for its lead concussion drug ONP-002 and a $16.5 million capital raise.

Oragenics, Inc. has successfully closed a public offering, raising approximately $16.5 million in gross proceeds through the sale of Series H Convertible Preferred Stock and Warrants, primarily to fund its ONP-002 concussion clinical trials and repay a $3 million bridge note.

Oragenics, Inc. announced a 1-for-30 reverse stock split, effective June 3, 2025, to meet NYSE American's continued listing standards and increase its share price.

Oragenics, Inc. provides an update on its Neurotrauma Medicine program during a webinar presented by its Scientific Advisory Board.

Oragenics, Inc. appoints Janet Huffman as CEO, approves a reverse stock split authorization, and amends its equity incentive plan following the annual shareholder meeting.

Oragenics has submitted its clinical trial protocol to the Health and Disability Ethics Committee (HDEC) in New Zealand for its Phase II clinical trial of ONP-002 for mild traumatic brain injury (mTBI) or concussion.

Oragenics, Inc. updated shareholders on its Q1 2025 strategic and financial progress, highlighting advancements in its lead therapeutic candidate, ONP-002, for concussion treatment.

Oragenics, Inc. has submitted its Investigators Brochure (IB) application in preparation for its Phase II clinical trial using ONP-002 in Australia, marking a significant step in developing a treatment for mild traumatic brain injury (mTBI).

Oragenics, Inc. announces the rescheduling of its 2024 Annual Meeting of Shareholders to May 16, 2025, and sets a new deadline of March 14, 2025, for shareholder proposals.

Oragenics, Inc. announces its Chief Medical Officer, Dr. James P. Kelly, will participate in the 12th Annual Brain Health Summit, focusing on concussion and traumatic brain injury (TBI) treatment.

Oragenics, Inc. announced the appointment of Janet Huffman as interim CEO and provided an update on strategic progress since its September 2024 capital raise, including advancements in clinical trial preparations for ONP-002.

Oragenics, Inc. appoints Janet Huffman as Interim CEO, increases her base salary by 10% to $275,000, and grants her a $75,000 bonus following the resignation of a director.

Oragenics has increased its share reserve for equity incentives, appointed a new interim CEO, and converted preferred shares to common stock, simplifying its capital structure.

Oragenics Inc. has decided not to renew the employment agreement of its President, J. Michael Redmond, which will terminate at the end of its initial term.

Oragenics Inc. will present at the Centurion One Capital 2nd Annual Bahamas Summit on October 22, 2024, with President Michael Redmond participating in a corporate presentation and Q&A session.

Oragenics Inc. has released an investor presentation, which will be used in discussions with potential investors and industry analysts.

Oragenics, Inc. has entered into an at-the-market sales agreement with Dawson James Securities to potentially sell up to $10 million of its common stock.

Oragenics has announced key milestones in the development of its concussion drug, ONP-002, including successful safety testing and preparations for Phase II clinical trials.

Oragenics Inc. has granted stock options to its President and CFO and rescheduled its 2023 Annual Meeting of Shareholders to December 11, 2024.